Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells

Trends in Endocrinology and Metabolism

Volumn 8, Issue 9, 1997, Pages 355-362

  Emons, Günter ^a   Ortmann, Olaf ^a   Schulz, Klaus Dieter ^a   Schally, Andrew V ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GROWTH FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; BREAST CANCER; CANCER INHIBITION; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; GROWTH INHIBITION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RECEPTOR DENSITY; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 0031438761     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(97)00155-0     Document Type: Short Survey

References (61)

1. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P: 1997. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67:917-922.
2. Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt K, Nieschlag E: 1992. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab 75:393-398.
3. Blankenstein MA, Henkelman MS, Klijn JMG: 1985. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol 21:1493-1499.
4. Bramley TA, McPhie CA, Menzies GS: 1994. Human placental gonadotropin-releasing hormone (GnRH) binding sites: III. Changes in GnRH binding levels with stage of gestation. Placenta 15:733-745.
5. Bützow R, Huhtaniemi I, Clayton R, Wahlström T, Anderson LC, Seppälä M: 1987. Cultured mammary carcinoma cells contain gonadotropin-releasing hormone-like immunoreactivity, GnRH binding sites and chorionic gonadotropin. Int J Cancer 39:498-501.
6. Chatzaki E, Bax CMR, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ: 1996, The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer and its relevance as an autocrine growth factor. Cancer Res 56:2055-2065.
7. Chegini N, Rong H, Dou Q, Kipersztok C, Williams RS: 1996. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GNRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J Clin Endocrinol Metab 81:3215-3221.
8. Connor JP, Buller RE, Conn PM: 1994. Effects of GnRH analogs on six ovarian cancer cell lines in culture. Gynecol Oncol 54:80-86.
9. Emons G, Schally AV: 1994. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers. Hum Reprod 9:1364-1379.
10. Emons G, Ortmann O, Becker M, et al.: 1993a. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 54: 5439-5446.
11. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD, Schally AV: 1993b. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77:1458-1464.
12. Emons G, Ortmann O, Schulz KD: 1996a. GnRH analogues in ovarian, breast and endometrial cancers. In Lunenfeld B, Insler V, eds. GnRH Analogues, The State of the Art 1996. Carnforth, Parthenon, pp 95-120.
13. Emons G, Ortmann O, Irmer G, Müller V, Schulz KD, Schally AV: 1996b. Treatment of ovarian cancer with LH-RH antagonists. In Filicori M, Flamigni C, eds. Treatment with GNRH Analogs: Controversies and Perspectives. Carnforth, UK, Parthenon, pp 165-172.
14. Emons G, Müller V, Ortmann O, et al.: 1996c. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 9:1129-1137.
15. Emons G, Ortmann O, Teichert HM, et al.: 1996d. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. Cancer 78:1452-1460.
16. Fekete M, Redding TW, Comaru-Schally AM, et al.: 1989a. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin and epidermal growth factor in rat and human prostatic cancers and in benign prostatic hyperplasia. Prostate 14:191-208.
17. 6]-luteinizing-hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3:137-147.
18. Furui T, Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T: 1995. Phosphotvrosine phosphatase activity in membranes from endometrial carcinoma. Oncol Rep 2:1055-1057.
19. Gallagher CJ, Oliver RTD, Oram DH, et al.: 1991. A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynaecol 98:1037-1041.
20. Harris N, Dutlow C, Eidne K, Dong KW, Roberts J, Millar RP: 1991. Gonadotropin-releasing-hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res 51:2577-2581.
21. Hershkovitz E, Marbach M, Bosin M, et al.: 1993. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin like growth factors. J Clin Endocrinol Metab 77:963-968.
22. + lymphocyte subpopulation in peripheral blood. Am J Reprod Immunol 33:243-252.
23. Hunter T: 1995. Protein kinases and phosphatases: the Yin and Yang of protein phosphorylation and signaling. Cell 80:225-236.
24. Imai A, Ohno T, Furui T, Takahashi K, Matsuda T, Tamaya T: 1993. Gonadotropin-releasing hormone stimulates phospholipase C but not protein phosphorylation/dephosphorylation in plasma membrane from human epithelial ovarian cancer. Int J Gynecol Cancer 3:311-317.
25. Imai A, Ohno T, Iida K, Fuseya T1 Furui T, Tamaya T: 1994a. Gonadotropin-releasing hormone receptors in gynecological tumors. Cancer 74:2555-2561.
26. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T: 1994b. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 55: 114-118.
27. Imai A, Takagi H, Furui T, Horibe S, Fuseya T, Tamaya T: 1996a. Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 77:132-137.
28. Imai A, Takagi H, Horibe S, Fuseya T, Tamaya T: 1996b. Coupling of gonadotropin releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 81:3249-3253.
29. Irmer G, Bürger C, Ortmann O, Schulz KD, Emons G: 1994, Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines. J Clin Endocrinol Metab 79:916-919.
30. Irmer G, Bürger C, Müller R, et al.: 1995. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55:817-822.
31. Jungwirth A, Galvan G, Pinski J, et al.: 1997a. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 32:164-172.
32. Jungwirth A, Pinski J, Galvan G, et al.: 1997b. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 33: 1141-1148.
33. Jungwirth A, Schally AV, Nagy A, et al.: 1997c. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 10:877-884.
34. Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD: 1992. Cloning, sequencing, and expression of human gonadotropin-releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 189:289-295.
35. Kakar SS, Grizzle WE, Neill JD: 1994. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 106:145-149.
36. Kéri G, Balogh A, Szöke B, Téplan J, Csuka O: 1991. Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell lines. Tumor Biol 12:61-67.
37. Kleinman D, Douvdevani A, Schally AV, Levy J, Sharoni Y: 1994, Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. Am J Obstet Gynecol 170:96-102.
38. Lee MT, Liebow C, Kramer AR, Schally AV: 1991. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation of tyrosine residues of specific substrates in various tumors. Proc Natl Acad Sci USA 88:1656-1660.
39. Levy J, Segal T, Wiznitzer A, Insler V, Sharoni Y: 1989. Molecular mechanisms of GnRH action on mammary tumors and uterine leiomyomata. In Vickery BH, Lunenfeld B, eds. GnRH Analogues in Cancer and Human Reproduction, vol 1. Dordrecht, Kluwer, pp 127-135.
40. Liebow C, Lee MT, Kramer AR, Schally AV: 1991. Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous receptor-stimulated tyrosine phosphorylation. Proc Natl Acad Sci USA 88:2244-2248.
41. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E, Motta M: 1993. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 76:797-800.
42. Loop SM, Gorder CA, Lewis SM, Saiers JH, Drivdahl RH, Ostenson RC: 1995. Growth inhibition of human prostatic cancer cells by an agonist of gonadotropin-releasing hormone. Prostate 26:179-188.
43. Manetta A, Gamboa-Vujicic L, Paredes P, et al.: 1995. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertil Steril 63:282-287.
44. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: 1985. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313:231-233.
45. Moretti MR, Montagnani Morelli M, Dondi D, et al.: 1996. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory action of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81:3930-3937.
46. Motta M, Dondi D, Moretti M, et al.: 1996. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. J Steroid Biochem Molec Biol 56:107-111.
47. Ohno T, Imai A, Furui T, Takahashi K, Tamaya T: 1993. Presence of gonadotropin-releasing hormone and his messenger ribonucleic acid in human ovarian epithelial carcinoma. Am J Obstet Gynecol 169:605-610.
48. Pályi I, Vincze B, Kálnay A, et al.: 1996. Effect of gonadotropin releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor-positive human cancer lines. Cancer Detect Prev 20:146-152.
49. Peng C, Fan NC, Ligier M, Väänänen J, Leung PCK: 1994. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology 135:1740-1745.
50. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J: 1990a. The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer 62:96-99.
51. Qayum A, Gullick W, Mellon K, et al.: 1990b. The partial purification and characterization of the GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 37:899-902.
52. Schally AV: 1994. Hypothalamic hormones from neuroendocrinology to cancer therapy. Anticancer Drugs 5:115-130.
53. Schally AV, Comaru-Schally AM: 1997. Hypothalamic and other peptide hormones. In Holland JF, Frei E III, Bast RR Jr, Kufe DE, Mortem DL, Weichselbaum RR, eds. Cancer Medicine, 4th ed. Baltimore, Williams and Wilkins, pp 1067-1086.
54. Schally AV, Nagy A, Szepeshazy K, et al.: 1996. LHRH analogs with cytotoxic radicals. In Filicori M, Flamigni C, eds. Treatment with GNRH Analogs: Controversies and Perspectives. Carnforth, UK, Parthenon, pp 33-44.
55. Segal-Abramson T, Giot J, Levy J, Sharoni Y: 1992. Guanine nucleotide modulations of high affinity gonadotropin-releasing hormone receptors in rat mammary tumors. Mol Cell Endocrinol 85:105-116.
56. Seppälä M, Wahlström T: 1980. Identification of luteinizing hormone-releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer 26:231-233.
57. Shirahige Y, Cook C, Pinski J, Halmos G, Nair R, Schally AV: 1994. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 5:1031-1035.
58. Stojilkovic SS, Catt KJ: 1995. Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Rec Prog Horm Res 30:161-205.
59. Thompson MA, Adelson MD, Kaufman LM: 1991. Lupron retards proliferation of ovarian tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72:1036-1041.
60. Yano T, Pinski J, Radulovic S, Schally AV: 1994a. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 91:1701-1704.
61. Yano T, Pinski J, Halmos G, Szepeshazi K, Schally AV: 1994b. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91:7090-7094.